Pharmaceutical preparation comprising an inhibitor of the integrin-MAP kinase interaction

摘要

Use of an agent in the manufacture of a medicament for the prophylaxis or treatment of cancer in a mammal where the agent binds to a MAP kinase such that binding of the MAP kinase to the integrin is inhibited. Preferably the agent binds to a binding domain of the MAPK for the integrin and is a peptide derived from the cytoplasmic domain of a B integrin preferably comprising a consensus MAP kinase binding motif. Preferably the agent comprises one of the following amino acid sequences RSKAKWQTGTNPLYR, RARAKWDTANNPLYK, RSRARYEMASNPLYR, RSKAKNPLYR, RARAKNPLYK, RSRARNPLYR, KAKLKQWNNDNPLFK, KAKLKNPLFK and may also comprise a signal peptide, for example, the K-FGF signal peptide. Preferably the MAP kinase is an ERK, JNK, or p38 kinase. Examples describe the disruption of the ERK2 integrin interaction in human colon cancer cell lines by B6 integrin derived peptides.